Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
larger decrease » marked decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
larger decrease » marked decrease (Expand Search)
-
2521
-
2522
-
2523
-
2524
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2525
-
2526
-
2527
-
2528
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2529
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2530
-
2531
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2532
-
2533
-
2534
-
2535
-
2536
-
2537
-
2538
-
2539
-
2540
Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.
Published 2025Subjects: